Inrebic, a once-daily oral capsule, is the second treatment approved in the U.S. for myelofibrosis. The drug is manufactured by Impact Biomedicines, a subsidiary of Celgene.
The drug, a kinase inhibitor, targets treatment-naive myelofibrosis, a bone marrow disorder that disrupts the normal production of blood cells.
The approval is the first new treatment for the disease in nearly a decade.
It also comes as a win for drug giant Bristol-Myers Squibb, which is finalizing its merger with Celgene.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.